Delighted to have officially joined UT Austin, Division of Gastroenterology & Hepatology as a Clinical Assistant Professor.
https://t.co/BqCgKBFJTo
📢 Neurogastroenterology & Motility Fellowship Opportunity
A fellowship position is available starting July 2026.
Please note: Visa sponsorship is not available
Interested candidates can contact Dr. Adam Farmer for more information.
New pub🚨
Just published @APandT
🎯 EDS patients exhibit heightened risk for GI (GERD, IBS, constipation) comorbidities, highlighting the importance of multidisciplinary approaches for effective management.
📖 https://t.co/Kp61xMGrGj
#GITwitter#MedTwitter@MayoClinicGIHep
Excited to share our latest study in BMJ Open on the relationship between MASLD/MASH and the risk of colorectal cancer and benign colorectal neoplasms 💥💥
Thanks to the stellar team @SLUgastro@washumedicine & @MahMadi90@MalekAyoubMD 🌟👏🏼
https://t.co/F5hiI03cSK
🚨New Publication!
"The Impact Of Opioid Use In Chronic Pancreatitis From 2004-2024: A Propensity-Matched Analysis Of 183,214 Individuals"
Opioid use in CP is associated with:
⬆️Acute-on-chronic pancreatitis (aHR 1.45)
⬆️All-cause mortality (aHR 1.90)
⬆️Healthcare resource utilization
🔗: https://t.co/WLkTthSjOA
Grateful to our exceptional team and mentors:
@MahMadi90@ibsdoc@AsbjornDrewes #DrOlesen @TarekNammour@DGonzalezMMD@Ayah__Obeid
#GITwitter #MedTwitter @SLUgastro@slusom
An amazing week at #ACG2025 ! presented multiple posters and was honored to receive the Presidential Poster Award for our study on EUS timing and treatment initiation for pancreatic lesions!
So grateful for my mentors and co-authors 🙌
#MedTwitter#GITwitter
More evidence supporting carvedilol as the beta blocker of choice for secondary EVH prophylaxis. Even better, carvedilol use was also associated with lower risk of further decompensation events in this population.
Check out our new study here:
https://t.co/Kcb18v3gWw
Our abstract on real-world variation in time to EUS for pancreatic lesions was selected as a Presidential Poster recipient at #ACG2025 !✨⚕️
Grateful to my mentors and collaborators for their guidance!
Our latest publication 🚨
"The Impact of MASLD on Autoimmune Hepatitis Outcomes: A Nationwide Analysis of 2880 Records"
In AIH patients, MASLD was linked to:
⬇️ 1-yr immunosuppressant use (HR 0.69)
⬆️ 10-yr risk of cirrhosis (HR 1.22)
⬆️ 10-yr risk of HCC (HR 2.03)
👉 Early detection & management of MASLD in patients with AIH is key.
🔗https://t.co/Qqh5YO0xKt
Thanks to our amazing team @DrDiabat@kymyves@BaselNaser89@MahMadi90 #DrSyn
#LiverTwitter #GITwitter #Hepatology @SLUgastro@slusom
📝🚨 New Publication Alert:
TLDR - Despite progress 📉, thousands still get surgery for benign polyps. We’re not quite out of the OR yet.
Link: https://t.co/1ODdmtKVrl
Our latest publication 🚨
"Trends in Surgical and Endoscopic Resection Intervention for Non-Malignant Colorectal Polyps over the Last Decade: A Nationwide Analysis"
📉 Surgery for non-malignant colorectal polyps is modestly declining (2014–2024) as EMR & ESD increase, yet avoidable surgeries persist—underscoring the need for better polyp characterization, broader access to expert endoscopists, and standardized quality metrics.
🔗: https://t.co/runOj8bM42
Thanks to our amazing team @MahMadi90@DGonzalezMMD@AhmadBazarbashi@ThomasRMcCarty3@Jarshah4
#GITwitter #MedTwitter #endoscopy #colorectalcancer